Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2010. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction and does not contain comprehensive financial statements.
Material Changes
The filing details a specific transaction involving Mr. D Pulman:
- Date of Exercise: March 12, 2010
- Shares Exercised: 17,858 Ordinary shares under the Annual Incentive Plan.
- Shares Sold: 7,621 shares sold on March 15, 2010.
- Sale Price: £12.44 per share.
- Purpose: To meet the tax liability arising from the exercise of the award.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the disclosed insider transaction.
Investor Verification Checklist
- Verify the total number of shares held by Mr. D Pulman following the sale of 7,621 shares.
- Confirm the tax liability calculation based on the exercise of 17,858 shares and the sale price of £12.44.
- Review the company's Annual Incentive Plan terms regarding share exercises and tax withholding procedures.